Skip to content
Screener

AbCellera Biologics Inc. ABCL Q2 2025 earnings

Reported August 7, 2025 · After market close

Revenue$17.1MBeat by $10.7M
EPS-$0.12Beat by $0.05
Revenue estimate$6.4M
EPS estimate-$0.17

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$5.3M
EPS estimate-$0.18

Financials

Q2 2025

Income statement

See full
Revenue$17.1M+133%
Operating income-$49.6M+46.9%
Net income-$34.7M+6.0%
EPS (diluted)-$0.12+7.7%

Balance sheet

See full
Cash & equivalents$117.4M-32.2%
Total debt$142.1M+97.2%
Total equity$1.0B-9.4%
Total assets$1.4B-0.7%

Cash flow

See full
Operating cash flow-$32.4M-8.1%
CapEx$13.4M-33.5%
Free cash flow-$45.8M+8.6%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$1.1B+26.2%
Enterprise value$1.12B+46.0%
P/S33.4×+7.1×

Profitability

See full
Operating margin-847.6%+35.7pp
Net margin-503.9%+47.7pp
FCF margin-422.8%-64.5pp

Returns & leverage

See full
Return on equity-15.6%+3.4pp
Debt / equity0.1×+0.1×
Current ratio11.1×+0.1×

Segments

By geography

See full
Canada$16.0M+144%
United States$2.8M+311%

By product

See full
Research fees$6.6M+21.7%

FAQ

When did AbCellera Biologics Inc. report Q2 2025 earnings?
AbCellera Biologics Inc. (ABCL) reported Q2 2025 earnings on August 7, 2025 after market close.
What were AbCellera Biologics Inc.'s Q2 2025 revenue and EPS?
AbCellera Biologics Inc. reported revenue of $17.1M and eps of $-0.12 for Q2 2025.
Did AbCellera Biologics Inc. beat estimates in Q2 2025?
Revenue beat the consensus estimate of $6.4M by $10.7M. EPS beat the consensus estimate of $-0.17 by $0.05.
How did AbCellera Biologics Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 133.3% from $7.3M a year earlier and eps grew 7.7% from $-0.13.
Where can I find AbCellera Biologics Inc.'s Q2 2025 SEC filings?
You can read the 8-K earnings release (0001628280-25-038927) and the 10-Q periodic report (0001703057-25-000011) directly on SEC EDGAR. The filing index links above go to sec.gov.